Reduction of in vivo binding of [3H]paroxetine in mouse brain by 3,4-methylenedioxymethamphetamine
Related Experiment Video
Updated: Oct 12, 2026
Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
Published on: August 6, 2013
1Department of Radiopharmaceutical Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences, University of Fukuyama, Japan.
Abstract:
The effects of 3,4-methylenedioxymethamphetamine (MDMA) on the in vivo binding of [3H]paroxetine, a potent and selective 5-hydroxytryptamine (5-HT; serotonin) uptake inhibitor, in the brain of the mouse were studied. The distribution of radioactivity in the brain of the mouse, after intravenous administration of [3H]paroxetine, was significantly altered by pretreatment with MDMA (15 mg/kg, i.p., 3 hr before). The hypothalamus/cerebellum and cerebral cortex/cerebellum ratios, as a function of time, were significantly decreased after the pretreatment with MDMA, indicating that the in vivo binding of [3H]paroxetine to uptake sites for 5-HT in the brain of the mouse was significantly decreased by MDMA. These ratios could reflect those of the total binding, to the non-specific binding and free ligand, since the cerebellum has very low levels of binding for [3H]paroxetine. Furthermore, these ratios decreased after pretreatment with MDMA, in a dose-dependent manner. However, the binding of [3H]paroxetine to membranes from the brain of the mouse in vitro was not altered by treatment with MDMA. The discrepancy between the in vivo binding and in vitro binding of [3H]paroxetine in the brain of the mouse is discussed.
Insights
3,4-methylenedioxymethamphetamine (MDMA) significantly reduced serotonin transporter binding in mouse brains in vivo. This effect was dose-dependent but not observed in vitro, suggesting complex interactions.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Serotonin transporter (SERT) plays a crucial role in regulating serotonergic neurotransmission.
- 3,4-methylenedioxymethamphetamine (MDMA) is known to affect serotonin levels.
- [3H]paroxetine is a selective radioligand for studying SERT binding.
Purpose of the Study:
- To investigate the in vivo effects of MDMA on the binding of [3H]paroxetine to serotonin transporters in the mouse brain.
- To compare in vivo and in vitro binding of [3H]paroxetine after MDMA treatment.
Main Methods:
- Mice were pretreated with MDMA (15 mg/kg, i.p.) 3 hours before intravenous administration of [3H]paroxetine.
- Brain tissue radioactivity distribution was analyzed to determine binding ratios (e.g., hypothalamus/cerebellum, cerebral cortex/cerebellum).
- In vitro binding assays were performed using mouse brain membranes and MDMA.
Main Results:
- MDMA pretreatment significantly altered the in vivo distribution of [3H]paroxetine in the mouse brain.
- Hypothalamus/cerebellum and cerebral cortex/cerebellum ratios decreased significantly over time post-MDMA administration.
- The observed decrease in binding ratios was dose-dependent.
- MDMA did not alter [3H]paroxetine binding to mouse brain membranes in vitro.
Conclusions:
- MDMA significantly decreases the in vivo binding of [3H]paroxetine to serotonin uptake sites in the mouse brain.
- The discrepancy between in vivo and in vitro results suggests MDMA-induced changes in transporter accessibility or function, rather than direct blockade of binding sites.
- Further research is needed to elucidate the mechanisms underlying MDMA's in vivo effects on serotonin transporter binding.
More Related Videos
Related Concept Videos
01:21Drugs Affecting Neurotransmitter Release or Uptake
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...